My ageing mind might be playing tricks, but I seem to recall that JP was asked about why Acadia hadn't pursued Fragile X with trofinetide and the response was that the phase 2 trial didn't provide robust enough results.
Was that at the AGM or in a webinar or a figment of my imagination?
Ann: Investor web conference presentation, 14 July 2023, page-35
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
-0.010(0.05%) |
Mkt cap ! $2.548B | |||
| Open | High | Low | Value | Volume |
| $19.92 | $20.04 | $19.81 | $364.2K | 18.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 62 | $19.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.97 | 45 | 3 |
View Market Depth
| Last trade - 11.06am 19/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |